New Strong Sell Stocks for March 11th
ALKS, BBSI and CBZ have been added to the Zacks Rank #5 (Strong Sell) List on March 11th, 2026.
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
ALKS beats Q4 earnings and revenue estimates, but shares fall 7%. The company announces a CEO transition plan.
Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $1.04 per share a year ago.
Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript
Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript
Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?
Here is how Alkermes (ALKS) and American Well Corporation (AMWL) have performed compared to their sector so far this year.
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Best Value Stocks to Buy for Jan.14
GES, NESR and ALKS made it to the Zacks Rank #1 (Strong Buy) value stocks list on Jan.14, 2026.
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside
Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS's robust legacy portfolio funds rapid R&D expansion, with Lybalvi sales up 32% and strong gross-to-net dynamics supporting operational profitability. Alixorexton's Phase 2 success in both narcolepsy types and idiopathic hypersomnia, plus a clean safety profile, significantly de-risk the clinical pipeline.
